New Cochrane Review Suggests PSA Blood Testing May Reduce Prostate Cancer Deaths, Shifting Medical Evidence

A significant shift in medical evidence has emerged from a comprehensive review published by the influential international science research organization Cochrane, suggesting that prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer. This finding, detailed in a review released on Thursday, has the potential to encourage wider adoption and reconsideration of PSA screening protocols, which have seen fluctuating recommendations over the past decade.

The first author of the Cochrane review, Juan Franco from Heinrich Heine University Düsseldorf in Germany, conveyed a message of "moderate certainty" regarding the screening test’s efficacy. Speaking at a press conference, Franco explained that the PSA test, which identifies elevated levels of the antigen as a potential indicator of prostate cancer, appears to lead to a reduction in disease-specific mortality. However, the review’s authors were careful to qualify these benefits, noting they are marginal. Analyzing data from six large-scale trials involving approximately 800,000 participants across Europe and North America, the review indicated that for every 1,000 men screened, approximately two fewer prostate cancer deaths were observed.

Despite this positive indication, the review’s authors stressed that their findings do not constitute an unqualified endorsement of PSA screening. They strongly advised men to engage in thorough discussions with their physicians to determine the individual advisability of the test. Nevertheless, the conclusion that PSA screening can indeed reduce mortality marks a substantial departure from the findings of the previous Cochrane review in 2013. That earlier review did not identify similar life-saving benefits, a conclusion that contributed to a decline in the favorability and use of PSA screening.

A Shifting Landscape: From Widespread Adoption to Skepticism and Back?

The trajectory of PSA testing has been dynamic. Initially embraced as a routine screening tool in the 1990s and widely used for approximately two decades, leading medical organizations began to discourage its use. Notably, the U.S. Preventive Services Task Force (USPSTF) revised its guidelines to recommend against routine PSA screening for all men. This shift began with older men aged 75 and above in 2008, and by 2012, the recommendation extended to all men, regardless of age.

At the time of these guideline changes, research struggled to demonstrate that widespread screening definitively saved lives. Instead, the focus increasingly turned to the identified harms of PSA testing. The widespread application of the test led to concerns about overdiagnosis and overtreatment. Many men were found to have low-grade, slow-growing prostate cancers – conditions that likely would not have caused them harm during their lifetime and from which they would have died of unrelated causes. These individuals, however, were subjected to the significant physical and emotional burdens associated with cancer diagnoses and subsequent treatments.

The implications of overtreatment were stark. Prostate biopsies, a common follow-up procedure after an elevated PSA, carry inherent risks, including infection. Surgical interventions to remove tumors could result in life-altering side effects such as erectile dysfunction. Radiotherapy and other aggressive treatment modalities also presented substantial risks and long-term consequences. Statistics at the time indicated that as many as half of all prostate cancers diagnosed in the U.S. might not have warranted aggressive treatment and could have been managed through active surveillance. This highlighted the considerable risk of potentially worsening a patient’s health while attempting to treat a condition that might never have posed a threat.

New Data, Renewed Perspectives

The latest Cochrane review incorporates a greater volume of long-term data, drawing significantly from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This study provided follow-up data extending up to 23 years, offering a more robust understanding of the long-term effects of PSA screening. The updated analysis confirms that PSA screening can have a role in patient care, but emphasizes the critical need for its judicious application.

Simpa Salami, a professor of urology at the University of Michigan, commented on the timeliness and significance of these findings. "This study is timely because I think it provides sufficient evidence to support that screening could be beneficial if it is offered appropriately to those who are most likely to benefit, and it could actually save lives," Salami stated.

Salami further elaborated that while PSA screening requires careful administration, the process is becoming less likely to trigger an unnecessary cascade of interventions. "We are doing better now in selecting patients for biopsy," he explained. "In the past, we would biopsy anyone with just an elevated PSA, but now we have other tools to further refine who should get a biopsy. We have biomarkers in urine, we have biomarkers in blood, we have MRI imaging to facilitate biopsies, such that we are actually maximizing the detection of high-grade prostate cancer and minimizing the detection of low-grade prostate cancer."

This evolution in diagnostic refinement suggests a more nuanced approach to PSA screening, moving beyond a singular reliance on the PSA level itself to a more comprehensive assessment of risk.

Contextualizing the Benefits: The Importance of Consistent Care

While the Cochrane review provides compelling evidence for the potential life-saving benefits of PSA screening, experts caution against misinterpreting the findings as a universal mandate for the test. The review itself does not offer specific guidelines or treatment recommendations, and its findings do not immediately alter current screening implementation protocols.

Otis Brawley, a professor of oncology and epidemiology at Johns Hopkins University’s Sidney Kimmel Comprehensive Cancer Center, underscored the importance of understanding the context in which these results were achieved. He stressed that the participants in the studies who experienced benefits were not merely tested once. Instead, they underwent regular testing over extended periods and actively collaborated with their physicians to interpret results and determine subsequent actions.

"In the United States, there are a whole bunch of people who think that means, ‘Oh, if I get a PSA [test], I am doing something to save my life’," Brawley observed. He contrasted this perception with the reality of the study participants’ engagement, highlighting that the observed benefits are contingent upon consistent medical care and proactive physician-patient relationships.

Brawley critiqued the prevalent practice of opportunistic PSA testing in the U.S., such as tests offered at community events or sporting gatherings. "It is not what is commonly done in the United States, which is getting your PSA drawn from a van parked at a state fair, a van in the parking lot of a church, or at a football party where it’s, ‘Come on in, see the game, and get your PSA drawn’," he stated. He argued that such ad-hoc testing, devoid of consistent medical oversight and follow-up, is unlikely to yield the same life-saving benefits demonstrated in controlled studies. The challenges in the American healthcare system regarding consistent medical care, accurate follow-ups, and appropriate treatments mean that PSA screening alone, without these essential components, may fall short of its potential.

The Doctor-Patient Relationship as a Crucial Determinant

Brawley emphasized the pivotal role of the doctor-patient relationship in maximizing the benefits of PSA screening while mitigating its risks. "I think the appropriate thing within the doctor-patient relationship is that a doctor ought to offer the test to the patient," he asserted, acknowledging the evidence of benefits while remaining explicit about the risks of overdiagnosis and overtreatment. Doctors who maintain ongoing relationships with their patients are better positioned to monitor PSA results over time and manage potential over-treatment. This sustained interaction allows for a more informed decision-making process regarding the necessity of biopsies and other interventions, based on a comprehensive understanding of the patient’s health trajectory.

Quantifying the Benefit: A Realistic Perspective

Brawley also highlighted the need for clarity regarding the precise magnitude of screening’s benefit in preventing deaths. "If you have 15 men who are going to die from prostate cancer, screening them in a program of high-quality screening over a period of 20 years will prevent 1 of the 15 men from dying," he stated, providing a concrete illustration of the impact. He pointed out a societal tendency in the U.S. to view every prostate cancer death as a failure of screening or physician interpretation. "People cannot understand that the majority of people who were going to die from prostate cancer will still die from prostate cancer whether they are screened or not," Brawley concluded, stressing that screening is not a panacea but rather a tool that, when used appropriately, can offer a specific, albeit modest, reduction in mortality for a subset of men.

The implications of this new Cochrane review are substantial, potentially prompting a recalibration of screening guidelines and a renewed emphasis on shared decision-making between physicians and patients. As medical professionals and policymakers digest these updated findings, the focus will likely remain on ensuring that PSA testing is implemented thoughtfully, with a clear understanding of both its potential benefits and its inherent risks.